Latest News
Notice of Amendment - Title 27, California Code of Regulations Amendment of Section 25703(a)(6): Quantitative Risk Assessment. The amendment modifies the calculation used to convert estimates of animal cancer potency to estimates of human cancer potency, which is used to calculate no significant risk levels for carcinogens listed under Proposition 65.
Nov 11, 2011, Program: Proposition 65
OEHHA posted the external peer review comments on the draft Public Health Goal for perchlorate in drinking water.
Nov 10, 2011, Program: Water
OEHHA has selected the chemicals below for the CIC’s review for possible listing under Proposition 65. OEHHA is initiating the development of hazard identification materials on C.I. Disperse Yellow 3, Dibenzanthracenes and dibenz[a,c]anthracene.
Nov 10, 2011, Program: Proposition 65
OEHHA released for public comment the Air Toxics "Hot Spots" Program Risk Assessment Guidelines: Technical Support Document for Exposure Assessment and Stochastic Analysis.
Nov 7, 2011, Program: Air
On September 23, 2011, OEHHA published a notice in the California Regulatory Notice Register (Register 2011, No. 38-Z) proposing to establish a specific regulatory level posing no significant risk for Imazalil by amending Title 27, California Code of Regulations, section 25705.
Nov 7, 2011, Program: Proposition 65
Estrogen–progestogen (combined) used as menopausal therapy, etoposide, etoposide in combination with cisplatin and bleomycin, methyl isobutyl ketone, MOPP (vincristine-prednisone-nitrogen mustard-procarbazine mixture) listed as known to cause cancer under Proposition 65.
Nov 4, 2011, Program: Proposition 65
Meeting Synopsis and Slide Presentations Carcinogen Identification Committee Meeting Held on October 12, 2011
Nov 2, 2011, Program: Proposition 65
Extension of public comment period regarding the removal of the reference to hexavalent chromium in Section 25707(b)(4) as posing no significant risk when ingested.
Oct 31, 2011, Program: Proposition 65
Tris(1,3-dichloro-2-propyl) phosphate (TDCPP) was listed effective 10/28/2011 as known to the State to cause cancer.
Oct 28, 2011, Program: Proposition 65
Extension of comment period regarding the establishment of a specific regulatory level posing no significant risk for Imazalil.
Oct 27, 2011, Program: Proposition 65